Enanta Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing oral drugs for viral infections and immunological diseases. The company collaborates with AbbVie to develop protease inhibitor compounds for chronic hepatitis C virus infection, marketed as VIEKIRA PAK® and MAVYRET®. Enanta's current clinical programs target treatments for respiratory syncytial virus (RSV) and inflammatory diseases by inhibiting key drivers of the type 2 immune response. The company operates primarily in the United States.
